Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

370
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
370
Equivalence: In Vitro and In Vivo Bioequivalence01:17

Equivalence: In Vitro and In Vivo Bioequivalence

327
Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
327
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

319
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
319
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

449
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
449
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

947
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
947
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

652
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
652

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantile Effect on Duration of Response: A Zero-Inflated Censored Regression Approach.

Pharmaceutical statistics·2025
Same author

FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Bayesian dynamic power prior borrowing for augmenting a control arm for survival analysis.

Journal of biopharmaceutical statistics·2025
Same author

Assessing predictive probability of success for future clinical trials.

Journal of biopharmaceutical statistics·2025
Same author

Using Propensity Score Weighting to Enhance the Operating Characteristics of Power Prior in Leveraging External Data to Augment a Traditional Clinical Study.

Pharmaceutical statistics·2025
Same author

A Bayesian framework for safety signal detection from medical device data.

Journal of biopharmaceutical statistics·2025
Same journal

Updated Recommendations for the Bioanalysis of Antibody-Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community.

The AAPS journal·2026
Same journal

In vivo Predictive Dissolution Test Using Biorelevant Bicarbonate Buffer for High-dose Free Acid Drug.

The AAPS journal·2026
Same journal

Whole-Body Pharmacokinetics of Ionizable Lipid, mRNA, and the Expressed Antibody following Intravenous Administration of mRNA-Loaded Lipid Nanoparticles.

The AAPS journal·2026
Same journal

Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation.

The AAPS journal·2026
Same journal

Guiding the Molnupiravir Tablet Formulation Using Physiologically Based Biopharmaceutics Modeling and Successfully Establishing Dissolution Safe Space.

The AAPS journal·2026
Same journal

Correction: Nanotechnology-enhanced Natural Products for Cancer Chemoprevention: Molecular Mechanisms and Clinical Translation.

The AAPS journal·2026
See all related articles

Related Experiment Video

Updated: Mar 25, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.3K

Evaluating In Vivo-In Vitro Correlation Using a Bayesian Approach.

Junshan Qiu1, Marilyn Martinez2, Ram Tiwari3

  • 1Office of Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. junshan.qiu@fda.hhs.gov.

The AAPS Journal
|February 21, 2016
PubMed
Summary
This summary is machine-generated.

A new Bayesian method enhances in vivo-in vitro correlation (IVIVC) analysis by incorporating both individual and population variability. This approach provides more accurate predictions of drug concentration-time profiles for diverse patient populations.

Keywords:
IVIVCMCMCWeibull distributionprobability matching priortolerance intervals

More Related Videos

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

21.5K
In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
13:17

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology

Published on: September 29, 2023

3.2K

Related Experiment Videos

Last Updated: Mar 25, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.3K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

21.5K
In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
13:17

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology

Published on: September 29, 2023

3.2K

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Biostatistics
  • Drug Development

Background:

  • Traditional linear regression models for in vivo-in vitro correlation (IVIVC) primarily assess population-level variability.
  • Existing confidence intervals do not adequately capture individual-level variability in drug concentration-time profiles.
  • There's a need for methods that predict individual patient responses based on IVIVC.

Purpose of the Study:

  • To develop a hierarchical Bayesian method for evaluating IVIVC.
  • To incorporate both individual- and population-level variability into IVIVC assessment.
  • To derive Bayesian tolerance intervals with frequentist validity for IVIVC.

Main Methods:

  • Development of a hierarchical Bayesian framework for IVIVC analysis.
  • Integration of individual and population variability parameters.
  • Application of Bayesian tolerance intervals with matching priors.

Main Results:

  • The proposed Bayesian method successfully incorporates both individual and population variability.
  • Generated Bayesian tolerance intervals demonstrate frequentist validity for IVIVC evaluation.
  • The method enables the generation of population profiles accounting for pharmacokinetic and product performance variability.

Conclusions:

  • The hierarchical Bayesian approach offers a robust method for IVIVC evaluation.
  • This method improves the prediction of individual drug concentration-time profiles.
  • It enhances the understanding of variability in drug product performance and subject pharmacokinetics.